<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567073</url>
  </required_header>
  <id_info>
    <org_study_id>AGLU03506</org_study_id>
    <nct_id>NCT00567073</nct_id>
  </id_info>
  <brief_title>Pompe Pregnancy Sub-Registry</brief_title>
  <official_title>A Sub-Registry to Observe the Effect of Myozyme (Alglucosidase Alfa) Treatment on Pregnancy and Infant Growth in Women With Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to track pregnancy outcomes in women with Pompe Disease and to follow
      infants born to women with Pompe Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design Time Perspective: Retrospective and Prospective
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Anticipated">January 31, 2034</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2034</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy outcomes, including complications, in women with Pompe disease who receive Myozyme during pregnancy and in women with Pompe disease that do not receive Myozyme</measure>
    <time_frame>10 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of infants born to women with Pompe disease for 3 years post-partum</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glycogen Storage Disease Type II (GSD-II)</condition>
  <condition>Pompe Disease (Late-onset)</condition>
  <condition>Glycogenesis 2 Acid Maltase Deficiency</condition>
  <arm_group>
    <arm_group_label>Pregnant Women Receiving Treatment for Pompe Disease</arm_group_label>
    <description>Pregnant Women with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)That Are Receiving Treatment of alglucosidase alpha (Myozyme)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnant Women Receiving No Treatment for Pompe Disease</arm_group_label>
    <description>Pregnant Women with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)That Are Not Receiving Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants Born to Mothers Receiving Treatment for Pompe</arm_group_label>
    <description>The Infants of Mothers with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)Where the Mothers Are Receiving Treatment of alglucosidase alpha (Myozyme)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants Born to Mothers Receiving No Treatment for Pompe</arm_group_label>
    <description>The Infants of Mothers with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)Where the Mothers Are Not Receiving Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alglucosidase alpha</intervention_name>
    <arm_group_label>Pregnant Women Receiving Treatment for Pompe Disease</arm_group_label>
    <other_name>Myozyme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Treatment</intervention_name>
    <arm_group_label>Infants Born to Mothers Receiving No Treatment for Pompe</arm_group_label>
    <arm_group_label>Infants Born to Mothers Receiving Treatment for Pompe</arm_group_label>
    <arm_group_label>Pregnant Women Receiving No Treatment for Pompe Disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant Females with Pompe disease and/or infants born to females with Pompe disease.
        Participants may or may not be receiving therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enroll in or agree to enroll in Pompe Registry

          -  Be pregnant or have been pregnant with appropriate medical documentation

          -  Provide a signed Patient Information and Authorization Form to participate in the
             sub-registry prior to any sub-registry related data collection is performed

        Exclusion Criteria:

          -  No Exclusion Criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>800-745-4447</phone>
    <email>MedInfo@genzyme.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Information</last_name>
    <phone>617-252-7832</phone>
    <email>MedInfo@genzyme.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigational Site Number 840040</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840025</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380008</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380006</name>
      <address>
        <city>Cagliari</city>
        <zip>09126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380005</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380004</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380013</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380007</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380009</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380002</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380011</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380003</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380015</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380012</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 1, 2007</study_first_submitted>
  <study_first_submitted_qc>December 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glycogen Storage Disease Type II (GSD-II)</keyword>
  <keyword>GSD-II</keyword>
  <keyword>Pompe Disease</keyword>
  <keyword>Pompe Disease (Late-Onset)</keyword>
  <keyword>Acid Maltase Deficiency Disease</keyword>
  <keyword>Glycogenosis II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Glycogen Storage Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

